Glucotrack to showcase CBGM at ADCES Annual Meeting in Phoenix.
PorAinvest
jueves, 31 de julio de 2025, 8:40 am ET1 min de lectura
GCTK--
The ADCES Annual Meeting is a premier event that brings together leading experts in diabetes care and education to discuss new insights within the diabetes space. Glucotrack's participation provides an excellent opportunity to engage with key stakeholders and share the latest developments in continuous blood glucose monitoring technology.
Glucotrack's CBGM represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. This approach addresses key limitations of current CGM technology, including the need for frequent sensor changes and the challenges associated with on-body wearables.
The company is preparing to begin its long-term early feasibility study following successful initial clinical validation. Glucotrack's CBGM is an Investigational Device and is limited by federal law to investigational use. The company aims to advance its technology towards a US pilot study, with the ultimate goal of improving the quality of life for people living with diabetes.
The poster presentation, titled "Endocrinologists’ Perspectives on an Implantable Continuous Blood Glucose Monitor," will be held on Saturday, August 9, from 12:00 PM to 1:00 PM MST. The session will provide insights into physician perspectives regarding the potential benefits and challenges of implantable continuous glucose monitoring technology.
For more information about Glucotrack’s CBGM, visit [Glucotrack's website](http://www.glucotrack.com).
References:
[1] https://www.globenewswire.com/news-release/2025/07/31/3124984/0/en/Glucotrack-to-Exhibit-at-2025-Association-of-Diabetes-Care-and-Education-Specialists-Annual-Meeting.html
[2] https://www.stocktitan.net/news/GCTK/glucotrack-to-exhibit-at-2025-association-of-diabetes-care-and-whrvv67xs5rl.html
Glucotrack, a medical device company focused on diabetes technology, will participate in the Association of Diabetes Care and Education Specialists' Annual Meeting in Phoenix, AZ. The company will showcase its Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a poster on physician perspectives regarding the technology. The ADCES conference brings together experts in diabetes care and education to discuss new insights in the field.
Glucotrack, Inc. (Nasdaq: GCTK), a medical device company specializing in diabetes technology, has announced its participation in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting, to be held from August 8-11, 2025, in Phoenix, AZ. The company will showcase its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a scientific poster on endocrinologist perspectives regarding implantable monitoring technology.The ADCES Annual Meeting is a premier event that brings together leading experts in diabetes care and education to discuss new insights within the diabetes space. Glucotrack's participation provides an excellent opportunity to engage with key stakeholders and share the latest developments in continuous blood glucose monitoring technology.
Glucotrack's CBGM represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. This approach addresses key limitations of current CGM technology, including the need for frequent sensor changes and the challenges associated with on-body wearables.
The company is preparing to begin its long-term early feasibility study following successful initial clinical validation. Glucotrack's CBGM is an Investigational Device and is limited by federal law to investigational use. The company aims to advance its technology towards a US pilot study, with the ultimate goal of improving the quality of life for people living with diabetes.
The poster presentation, titled "Endocrinologists’ Perspectives on an Implantable Continuous Blood Glucose Monitor," will be held on Saturday, August 9, from 12:00 PM to 1:00 PM MST. The session will provide insights into physician perspectives regarding the potential benefits and challenges of implantable continuous glucose monitoring technology.
For more information about Glucotrack’s CBGM, visit [Glucotrack's website](http://www.glucotrack.com).
References:
[1] https://www.globenewswire.com/news-release/2025/07/31/3124984/0/en/Glucotrack-to-Exhibit-at-2025-Association-of-Diabetes-Care-and-Education-Specialists-Annual-Meeting.html
[2] https://www.stocktitan.net/news/GCTK/glucotrack-to-exhibit-at-2025-association-of-diabetes-care-and-whrvv67xs5rl.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios